Robert Zivadinov discusses real world studies and how they add to our understanding of the multiple sclerosis disease course and patient management. He also gives his views on the most useful MRI measures of treatment effect in routine clinical use and the significance of grey matter pathology in multiple sclerosis.
Disclosures: Robert Zivadinov received personal compensation from Teva Pharmaceuticals, Biogen Idec, EMD Serono, Genzyme-Sanofi, Claret Medical, IMS Health and Novartis for speaking and consultant fees. He received financial support for research activities from Teva Pharmaceuticals, Genzyme-Sanofi, Novartis, Claret Medical, Intekrin and IMS Health.
